Zymeworks Upgraded at Leerink Partnrs
ZYME Stock | USD 13.95 0.55 3.79% |
About 72% of Zymeworks Common's investor base is looking to short. The analysis of the overall investor sentiment regarding Zymeworks Common Stock suggests that many traders are alarmed. The current market sentiment, together with Zymeworks Common's historical and current headlines, can help investors time the market. In addition, many technical investors use Zymeworks Common Stock stock news signals to limit their universe of possible portfolio assets.
Zymeworks |
Zymeworks was upgraded by research analysts at Leerink Partnrs from a hold rating to a strong-buy rating in a report released on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for Zymeworks Q4 2024 earnings at 0.70 EPS. A number of other research analysts have also recently issued reports on the
Read at thelincolnianonline.com
Zymeworks Common Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Zymeworks Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Zymeworks Common Fundamental Analysis
We analyze Zymeworks Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zymeworks Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zymeworks Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Zymeworks Common is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Zymeworks Common Stock Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zymeworks Common stock to make a market-neutral strategy. Peer analysis of Zymeworks Common could also be used in its relative valuation, which is a method of valuing Zymeworks Common by comparing valuation metrics with similar companies.
Peers
Zymeworks Common Related Equities
TERN | Terns Pharmaceuticals | 3.41 | ||||
MRSN | Mersana Therapeutics | 3.04 | ||||
BLUE | Bluebird Bio | 2.44 | ||||
CYTK | Cytokinetics | 1.74 | ||||
SNDX | Syndax Pharmaceuticals | 0.48 | ||||
TVTX | Travere Therapeutics | 0.97 | ||||
ARWR | Arrowhead Pharmaceuticals | 1.03 | ||||
BPMC | Blueprint Medicines | 1.12 | ||||
PRQR | ProQR Therapeutics | 1.61 | ||||
DAWN | Day One | 1.81 | ||||
APLS | Apellis Pharmaceuticals | 2.23 | ||||
ALEC | Alector | 3.09 | ||||
AKRO | Akero Therapeutics | 3.94 | ||||
PTGX | Protagonist Therapeutics | 4.65 | ||||
STOK | Stoke Therapeutics | 5.30 | ||||
ANNX | Annexon | 5.31 | ||||
RLAY | Relay Therapeutics | 6.00 | ||||
INZY | Inozyme Pharma | 6.09 | ||||
RVMD | Revolution Medicines | 6.89 | ||||
ZNTL | Zentalis Pharmaceuticals | 8.20 | ||||
EDIT | Editas Medicine | 9.59 | ||||
YMAB | Y MAbs | 10.35 | ||||
CABA | Cabaletta Bio | 13.80 |
Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |